Related Experiment Video
Updated: Jan 17, 2026
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
Cardiovascular-related hospital visits amongst oncology patients receiving immune checkpoint inhibitors: a
Wei Fang Dai1, Steven Habbous2, Andrew Yan3
1Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada; Canadian Centre for Applied Research in Cancer Control, Toronto, ON, Canada.
Introduction:
Immune checkpoint inhibitors (ICIs) have substantially improved the clinical outcomes for many cancer patients. However, these treatments are potentially associated with serious cardiovascular adverse events.
Methods:
We identified a population-based, retrospective cohort of oncology patients who started ICIs treatments between September 1st, 2012 and August 31st, 2019, in Ontario, Canada. The primary outcome was the incidence of cardiovascular-related hospital visits between initiation of ICI to 90 days after the last dose of ICI. Cumulative incidence functions were used to estimate the incidence of cause-specific cardiovascular-related hospital visits, accounting for the competing risks of all-cause mortality.
Results:
A total of 5725 cancer patients (median age 68 years and 59.4 % male) received ICI, of which 556 (9.7 %) individuals had hospital visits due to cardiovascular-related adverse events. Amongst patients with cardiovascular-related hospital visits, 284 (51 %) were hospitalized and 88 (15.8 %) required intensive care unit monitoring. Of the 0.9 % hospital visits due to myocarditis or pericarditis, the median time from ICI initiation to hospital visits was 63 days (Q1-Q3: 23-128). The one-year cumulative incidence of cardiovascular-related hospital visit was higher for patients with prior cardiovascular history (15.2 %; 95 % CI: 12.2-18.4 %) than those without (8.7 %; 95 % CI: 7.9-9.5 %) (p < 0.001). Amongst the 9.7 % ICI-treated patients with cardiovascular-related hospital visits, the median overall survival was 2.9 months (95 % CI: 2.24-3.52). Patients who required ICU stay had worse survival outcomes (median OS = 2.1 months) compared to those who were not hospitalized for the cardiovascular-related hospital visits (median OS = 2.5 months).
Conclusion:
In a population-based study, cancer patients treated with ICIs had a high incidence of cardiovascular-related hospital visits. Patients with prior cardiac disease are more likely to have a cardiovascular-related hospital visit. The survival outcomes following cardiovascular-related hospital visits is poor amongst cancer patients treated with ICI.
More Related Videos
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
09:04Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
Related Concept Videos
01:27Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:21Cancer Survival Analysis
01:27Tumor Immunotherapy
01:19Psychoneuroimmunology: Diabetes and Cancer
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...